

Liver Product References



Polachi, N., Bai, G., Li, T., Chu, Y., Wang, X., Li, S., Gu, N., Wu, J., Li, W., Zhang, Y., Zhou, S., Sun, H., & Liu, C. (2016). Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review. *European journal of medicinal chemistry*, 123, 577–595. <https://doi.org/10.1016/j.ejmech.2016.07.070>

Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-González, A., Esquivel-Soto, J., Esquivel-Chirino, C., García-Luna Y González-Rubio, M., Gayosso-de-Lucio, J. A., & Morales-González, J. A. (2014). Hepatoprotective effect of silymarin. *World journal of hepatology*, 6(3), 144–149. <https://doi.org/10.4254/wjh.v6.i3.144>

Karimi, G., Vahabzadeh, M., Lari, P., Rashedinia, M., & Moshiri, M. (2011). "Silymarin", a promising pharmacological agent for treatment of diseases. *Iranian journal of basic medical sciences*, 14(4), 308–317.

Kaplowitz N. (1981). The importance and regulation of hepatic glutathione. *The Yale journal of biology and medicine*, 54(6), 497–502.

Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021). Changes in Glutathione Content in Liver Diseases: An Update. *Antioxidants (Basel, Switzerland)*, 10(3), 364. <https://doi.org/10.3390/antiox10030364>

Schmitt, B., Vicenzi, M., Garrel, C., & Denis, F. M. (2015). Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study. *Redox biology*, 6, 198–205. <https://doi.org/10.1016/j.redox.2015.07.012>

Cook S. *Natural Medicine Journal Research Guide*. 2017.

Forman HJ, Zhang H, Rinna A. *Molecular Aspects of Medicine*. 2009;30(1-2):1-12.

Lushchak VI. *Journal of Amino Acids*. 2012;2012.

Richie JP, Nichenametla S, Neidig W, et al. *European Journal of Nutrition*. 2015;54(2):251-263.

Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J. S., Schell, T. D., & Richie, J. P., Jr (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. *European journal of clinical nutrition*, 72(1), 105–111.
<https://doi.org/10.1038/ejcn.2017.132>

Shetty, S. N., Mengi, S., Vaidya, R., & Vaidya, A. D. (2010). A study of standardized extracts of *Picrorhiza kurroa* Royle ex Benth in experimental nonalcoholic fatty liver disease. *Journal of Ayurveda and integrative medicine*, 1(3), 203–210. <https://doi.org/10.4103/0975-9476.72622>

Verma, P. C., Basu, V., Gupta, V., Saxena, G., & Rahman, L. U. (2009). Pharmacology and chemistry of a potent hepatoprotective compound Picroliv isolated from the roots and rhizomes of *Picrorhiza kurroa* royle ex benth. (kutki). *Current pharmaceutical biotechnology*, 10(6), 641–649. <https://doi.org/10.2174/138920109789069314>

Vang, S., Longley, K., Steer, C. J., & Low, W. C. (2014). The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. *Global advances in health and medicine*, 3(3), 58–69. <https://doi.org/10.7453/gahmj.2014.017>

Amaral, J. D., Viana, R. J., Ramalho, R. M., Steer, C. J., & Rodrigues, C. M. (2009). Bile acids: regulation of apoptosis by ursodeoxycholic acid. *Journal of lipid research*, 50(9), 1721–1734. <https://doi.org/10.1194/jlr.R900011-JLR200>

Invernizzi, P., Setchell, K. D., Crosignani, A., Battezzati, P. M., Larghi, A., O'Connell, N. C., & Podda, M. (1999). Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. *Hepatology (Baltimore, Md.)*, 29(2), 320–327. <https://doi.org/10.1002/hep.510290220>

Invernizzi, P., Setchell, K. D., Crosignani, A., Battezzati, P. M., Larghi, A., O'Connell, N. C., & Podda, M. (1999). Differences in the metabolism and disposition of ursodeoxycholic acid and of

its taurine-conjugated species in patients with primary biliary cirrhosis. *Hepatology (Baltimore, Md.)*, 29(2), 320–327. <https://doi.org/10.1002/hep.510290220>

Setchell, K. D., Rodrigues, C. M., Podda, M., & Crosignani, A. (1996). Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. *Gut*, 38(3), 439–446. <https://doi.org/10.1136/gut.38.3.439>

Ben Mosbah, I., Alfany-Fernández, I., Martel, C., Zaouali, M. A., Bintanel-Morcillo, M., Rimola, A., Rodés, J., Brenner, C., Roselló-Catafau, J., & Peralta, C. (2010). Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. *Cell death & disease*, 1(7), e52. <https://doi.org/10.1038/cddis.2010.29>

Gao, X., Fu, L., Xiao, M., Xu, C., Sun, L., Zhang, T., Zheng, F., & Mei, C. (2012). The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress. *Basic & clinical pharmacology & toxicology*, 111(1), 14–23. <https://doi.org/10.1111/j.1742-7843.2011.00854.x>

Diwan, V., Poudyal, H., & Brown, L. (2013). Piperine attenuates cardiovascular, liver and metabolic changes in high carbohydrate, high fat-fed rats. *Cell biochemistry and biophysics*, 67(2), 297–304. <https://doi.org/10.1007/s12013-011-9306-1>

Fernández-Lázaro, D., Mielgo-Ayuso, J., Córdova Martínez, A., & Seco-Calvo, J. (2020). Iron and Physical Activity: Bioavailability Enhancers, Properties of Black Pepper (Biperine®) and Potential Applications. *Nutrients*, 12(6), 1886. <https://doi.org/10.3390/nu12061886>

Srinivasan K. (2007). Black pepper and its pungent principle-piperine: a review of diverse physiological effects. *Critical reviews in food science and nutrition*, 47(8), 735–748. <https://doi.org/10.1080/10408390601062054>